Medicines with the Active Ingredient Tocilizumab (Atc: L04ac07 - for Subcutaneous Use) The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for drugs with the active ingredient tocilizumab (ATC: L04AC07 - for subcutaneous use) as part of a so-called open-house model. Under the specification of uniform contract conditionsn as well as a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130 a Paragraph 8 SGB V for the aforementioned active ingredients or medicinesn. Interested pharmaceutical companies can request the participation documents and the respective contract from the contact address mentioned. The prerequisite for concluding a contract is that the interested pharmaceutical company has completed the requested participation documentsconstantly filled out and signed. Medicines with the active ingredient Tocilizumab (ATC: L04AC07 - for subcutaneous use) Doc Title: Drugs with the active ingredient Tocilizumab (ATC: L04AC07 - for subcutaneous use) Contract Type: supplies AOK SAXONY - ANHALT Address: Lüneburger Str. 4 Town: Magdeburg Nuts Code: DE138 - Konstanz Postal Code: 39106 Contact Point: Justiciariate Process Office Phone: +49 3912878-45327 Fax: +49 3912878-845327 openhouse@san.aok.de Tender Notice International Competitive Bidding 719406-2023 Germany GT-92809880

Germany